ELUTIA INC. - CLASS A COMMON STOCK

Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

06 Jan 2025 07:00:01 By Nasdaq GlobeNewswire

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

13 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

29 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

23 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

18 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia Celebrates First Year

06 Sep 2024 15:23:52 By Nasdaq GlobeNewswire

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

05 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Participate in Upcoming Investor Conferences

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Announces Second Quarter 2024 Results

07 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

31 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

30 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

11 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Elutia Announces $13.26 Million Registered Direct Offering

17 Jun 2024 07:01:00 By Nasdaq GlobeNewswire

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

17 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

02 May 2024 15:05:00 By Nasdaq GlobeNewswire